Novogen Announces Filing of Key Patent Application
Novogen is pleased to announce the filing of a provisional patent application
covering the novel technology associated with the manufacture and use of it new
class of molecules referred to as `super-benzopyrans'.
The invention is based on technology that Novogen acquired when it purchased
Triaxial Pharmaceuticals Pty Ltd on 7 Dec 2012. Triaxial had developed a novel
manufacturing process that involved chemically `bending' molecules to allow the
insertion of atoms not previously possible. The Triaxial goal was the ability to
design and build molecules to suit particular therapeutic applications. The initial
result of this technology was the creation of an entirely new family of
compounds known as super-benzopyrans, hitherto impossible to manufacture
by existing techniques, and displaying a range of anti-cancer functions not
In the 2 months since the merger, Novogen has been conducting a series of
manufacturing studies designed to strengthen its patent position through
`reduction to practice', a key requirement for sound patent protection. These
studies have focused on the Company's inaugural drug candidate, CS-6, with the
manufacturing process now in place and able to produce the quantities of drug
required for its developmental program.
Provisional patent application No 2012905600 covers the three cornerstones of
patent protection around Novogen's initial family of super-benzopyrans: method
of manufacture, method of use, and composition of matter.
Dr Andrew Heaton, Novogen Chief Scientist, said, " the design and manufacturing
technology that is the basis of the Novogen technology, in our view heralds a new
era in drug discovery, and not just in the oncology field."
He added, "the ability to create a potent anti-cancer drug such as CS-6, and to
then add a further layer of design to improve its ability to attack cancer cells, and
then to add a further design layer to increase the likelihood of it being able to
cross the blood-brain barrier, is a practical example of what is achievable with
Professor Graham Kelly, Novogen CEO, said, "lodging this patent application
marks two milestones. The first is our overriding efforts to protect our valuable
intellectual property. The second is that we have achieved the means to
manufacture CS-6 economically and efficiently, something that is essential to our
objective of taking CS-6 into humans with primary brain cancer in 2014.
Novogen Ltd is a public Australian biotechnology company whose shares trade
on both the ustralian Stock Exchange (symbol `NRT') and N SD Q (symbol
`NVGN'). The Company is based in Sydney, ustralia and is focused on the
development of a family of novel anti-cancer drugs based on super-benzopyran
and `stealth' drug technologies. The Company's inaugural drug candidate is CS-6.
CS-6 belongs to a new class of drug candidates known (structurally) as super-
benzopyrans displaying potent anti-cancer activity and demonstrating increased
bio-availability to cancer cells (`stealth' technology). CS-6 shows broad anti-
proliferative and cytotoxic activity against human cancer cells, with particular
activity against human glioblastoma cells. CS-6 also has been designed
deliberately to meet the major known criteria for crossing the blood-brain
barrier, and for that reason is being developed as a first-line for the treatment of
glioblastoma multiforme, the main form of primary brain cancer.